| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11116724 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10610485 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9855215 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9259427 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10231927 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
Xatmep is owned by Azurity.
Xatmep contains Methotrexate Sodium.
Xatmep has a total of 5 drug patents out of which 0 drug patents have expired.
Xatmep was authorised for market use on 25 April, 2017.
Xatmep is available in solution;oral dosage forms.
Xatmep can be used as treatment of juvenile rheumatoid arthritis, a method for treating acute lymphoblastic leukemia.
The generics of Xatmep are possible to be released after 02 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-137) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-138) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 25, 2024 |
Drugs and Companies using METHOTREXATE SODIUM ingredient
Market Authorisation Date: 25 April, 2017
Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis
Dosage: SOLUTION;ORAL
XATMEP family patents
